The intractability of the crisis makes the Bezos-Buffett-Dimon alliance alluring
With the U.S. health-care system appearing incapable of taming runaway price inflation, Jeff Bezos, Warren Buffett, and Jamie Dimon think they can do better. Perhaps only titans with the resources of Amazon.com, Berkshire Hathaway, and JPMorgan Chase can contemplate such a thing. But changing the convoluted practices that determine drug costs will require them to take on powerful players who are already fighting among themselves.
Pharmaceutical companies have come under fire for the ever-rising five- and six-figure prices they charge for life- sustaining drugs. They say those numbers don’t tell the whole story, because middlemen—the pharmacy benefit managers (PBMs) and the insurance companies they work for—collect discounts that aren’t always passed on to patients. The industry is so emphatic about this argument that its lobbying group started a consumer website in January effectively waging war against the PBMs. Big Pharma’s battle cry represents a previously unthinkable rift between two big forces in health care that for years quietly settled their differences away from public view.
At stake is how the spoils of pricey drugs are divvied up in complex and shrouded negotiations among drugmakers, PBMs, insurers, wholesalers, and giant retail pharmacy chains. Consider Humalog, an Eli Lilly & Co. insulin drug, which in recent years has more than tripled in price, to $275 per vial, drawing their of lawmakers, patients, and consumer activists. But the company doesn’t keep even 20 percent of that list price. Most of it flows to middlemen in rebates and other discounts, according to SSR Health LLC, an investment research firm. Rebate deals are being set up for other expensive drugs, such as Humira, AbbVie Inc.’s rheumatoid arthritis blockbuster, which costs more than $4,800 a month, and Harvoni, Gilead Sciences Inc.’s hepatitis C cure, which lists at $94,500 for a 12-week treatment.
هذه القصة مأخوذة من طبعة February 19, 2018 من Bloomberg Businessweek.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة February 19, 2018 من Bloomberg Businessweek.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Instagram's Founders Say It's Time for a New Social App
The rise of AI and the fall of Twitter could create opportunities for upstarts
Running in Circles
A subscription running shoe program aims to fight footwear waste
What I Learned Working at a Hawaiien Mega-Resort
Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.
How Noma Will Blossom In Kyoto
The best restaurant in the world just began its second pop-up in Japan. Here's what's cooking
The Last-Mover Problem
A startup called Sennder is trying to bring an extremely tech-resistant industry into the age of apps
Tick Tock, TikTok
The US thinks the Chinese-owned social media app is a major national security risk. TikTok is running out of ways to avoid a ban
Cleaner Clothing Dye, Made From Bacteria
A UK company produces colors with less water than conventional methods and no toxic chemicals
Pumping Heat in Hamburg
The German port city plans to store hot water underground and bring it up to heat homes in the winter
Sustainability: Calamari's Climate Edge
Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment
New Money, New Problems
In Naples, an influx of wealthy is displacing out-of-towners lower-income workers